You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDapagliflozin
Accession NumberDB06292
TypeSmall Molecule
GroupsApproved
DescriptionDapagliflozin is indicated for the management of diabetes mellitus type 2, and functions to improve glycemic control in adults when combined with diet and exercise. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor, which prevents glucose reabsorption in the kidney. Using dapagliflozin leads to heavy glycosuria (glucose excretion in the urine), which can lead to weight loss and tiredness. Dapagliflozin was approved by the FDA on Jan 08, 2014. Dapagliflozin is not recommended for patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Structure
Thumb
Synonyms
(2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
External Identifiers
  • BMS 512148
  • BMS-512148
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EdistrideFilm-coated tablet5 mgOral useAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideFilm-coated tablet10 mgOral useAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideFilm-coated tablet10 mgOral useAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideFilm-coated tablet5 mgOral useAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideFilm-coated tablet10 mgOral useAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideFilm-coated tablet5 mgOral useAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideFilm-coated tablet10 mgOral useAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideFilm-coated tablet5 mgOral useAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideFilm-coated tablet5 mgOral useAstra Zeneca Ab2015-11-09Not applicableEu
EdistrideFilm-coated tablet10 mgOral useAstra Zeneca Ab2015-11-09Not applicableEu
Farxigatablet, film coated5 mg/1oralE.R. Squibb & Sons, L.L.C.2014-01-08Not applicableUs
Farxigatablet, film coated10 mg/1oralE.R. Squibb & Sons, L.L.C.2014-01-08Not applicableUs
Farxigatablet, film coated5 mg/1oralAstra Zeneca Pharmaceuticals Lp2015-01-05Not applicableUs
Farxigatablet, film coated10 mg/1oralAstra Zeneca Pharmaceuticals Lp2015-01-05Not applicableUs
ForxigaFilm-coated tablet10 mgOral useAstra Zeneca Ab2012-11-12Not applicableEu
Forxigatablet5 mgoralAstrazeneca Canada Inc2015-01-16Not applicableCanada
ForxigaFilm-coated tablet5 mgOral useAstra Zeneca Ab2012-11-12Not applicableEu
ForxigaFilm-coated tablet10 mgOral useAstra Zeneca Ab2012-11-12Not applicableEu
ForxigaFilm-coated tablet5 mgOral useAstra Zeneca Ab2012-11-12Not applicableEu
Forxigatablet10 mgoralAstrazeneca Canada Inc2015-01-16Not applicableCanada
ForxigaFilm-coated tablet5 mgOral useAstra Zeneca Ab2012-11-12Not applicableEu
ForxigaFilm-coated tablet10 mgOral useAstra Zeneca Ab2012-11-12Not applicableEu
ForxigaFilm-coated tablet5 mgOral useAstra Zeneca Ab2012-11-12Not applicableEu
ForxigaFilm-coated tablet10 mgOral useAstra Zeneca Ab2012-11-12Not applicableEu
ForxigaFilm-coated tablet10 mgOral useAstra Zeneca Ab2012-11-12Not applicableEu
ForxigaFilm-coated tablet5 mgOral useAstra Zeneca Ab2012-11-12Not applicableEu
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
XigduoAstrazeneca Canada Inc
Xigduo XRAstra Zeneca Pharmaceuticals Lp
Salts
Name/CASStructureProperties
Dapagliflozin propanediol monohydrate
960404-48-2
Thumb
  • InChI Key: GOADIQFWSVMMRJ-UPGAGZFNSA-N
  • Monoisotopic Mass: 502.1969604
  • Average Mass: 502.99
DBSALT001101
Categories
UNII1ULL0QJ8UC
CAS number461432-26-8
WeightAverage: 408.873
Monoisotopic: 408.133966239
Chemical FormulaC21H25ClO6
InChI KeyJVHXJTBJCFBINQ-ADAARDCZSA-N
InChI
InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
IUPAC Name
(2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES
CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[[email protected]](CO)[C@@H](O)[[email protected]](O)[[email protected]]2O)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassGlycosyl compounds
Direct ParentPhenolic glycosides
Alternative Parents
Substituents
  • Phenolic glycoside
  • Diphenylmethane
  • C-glycosyl compound
  • Phenol ether
  • Halobenzene
  • Chlorobenzene
  • Alkyl aryl ether
  • Benzenoid
  • Oxane
  • Monosaccharide
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Secondary alcohol
  • Polyol
  • 1,2-diol
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Primary alcohol
  • Organochloride
  • Organohalogen compound
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationDapagliflozin is indicated for adjunct management of glycemic control in patients with type 2 diabetes mellitus, in combination with diet and exercise.
PharmacodynamicsIncreases in the amount of glucose excreted in the urine were observed in healthy subjects and in patients with type 2 diabetes mellitus following the administration of dapagliflozin. A Dapagliflozin dose of 10 mg per day in patients with type 2 diabetes mellitus for 12 weeks resulted in excretion of approximately 70 grams of glucose in the urine per day at week 12. A near maximum glucose excretion was observed at the dapagliflozin daily dose of 20 mg. This urinary glucose excretion with dapagliflozin also results in increases in urinary volume.
Mechanism of actionA competitive inhibitor of the sodium-glucose transport subtype 2 protein, dapagliflozin blocks glucose reabsorption into the kidney, resulting in the elimination of blood glucose through the urine.
Related Articles
AbsorptionCmax is about 1 hour. (Obtained from 6 adult men in a fasted state administered a 50mg dose). 1.6% of unchanged dapagliflozin was found in the urine. A high-fat meal (52% caloric content) had no significant effect on previous pharmacokinetic parameters.
Volume of distributionNot Available
Protein binding91%.
Metabolism

Dapagliflozin 3-O-glucuronide is the primary metabolite of dapagliflozin, with 61% of the dapagliflozin dose recovered in the urine as this metabolite. The metabolism of dapagliflozin is primarily mediated by UGT1A9-dependent glucuronide conjugation. The major metabolite, dapagliflozin 3-O-glucuronide, is not an SGLT2 inhibitor.

SubstrateEnzymesProduct
Dapagliflozin
dapagliflozin 3-O-glucuronideDetails
Route of eliminationNot Available
Half life13.8 hours with the consumption of a 50 mg dose.
Clearance

Oral plasma clearance of 4.9 mL/min/kg, and a renal clearance of 5.6 mL/min.

ToxicityCompared to placebo-treated patients, patients with moderate renal impairment treated with dapagliflozin did not have improvement in glycemic control and had more renal-related adverse reactions and more bone fractures; therefore, dapagliflozin should not be initiated in this population. Based on its mechanism of action, dapagliflozin is not expected to be effective in patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m2) or ESRD.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal AbsorptionNot AvailableNot Available
Blood Brain BarrierNot AvailableNot Available
Caco-2 permeableNot AvailableNot Available
P-glycoprotein substrateNot AvailableNot Available
P-glycoprotein inhibitor INot AvailableNot Available
P-glycoprotein inhibitor IINot AvailableNot Available
Renal organic cation transporterNot AvailableNot Available
CYP450 2C9 substrateNot AvailableNot Available
CYP450 2D6 substrateNot AvailableNot Available
CYP450 3A4 substrateNot AvailableNot Available
CYP450 1A2 substrateNot AvailableNot Available
CYP450 2C9 inhibitorNot AvailableNot Available
CYP450 2D6 inhibitorNot AvailableNot Available
CYP450 2C19 inhibitorNot AvailableNot Available
CYP450 3A4 inhibitorNot AvailableNot Available
CYP450 inhibitory promiscuityNot AvailableNot Available
Ames testNot AvailableNot Available
CarcinogenicityNot AvailableNot Available
BiodegradationNot AvailableNot Available
Rat acute toxicityNot AvailableNot applicable
hERG inhibition (predictor I)Not AvailableNot Available
hERG inhibition (predictor II)Not AvailableNot Available
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Film-coated tabletOral use10 mg
Film-coated tabletOral use5 mg
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral5 mg/1
Tabletoral10 mg
Tabletoral5 mg
Tabletoral
Tablet, film coated, extended releaseoral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6414126 No2000-10-042020-10-04Us
US6515117 No2000-10-042020-10-04Us
US6936590 No2000-10-042020-10-04Us
US7851502 No2008-08-192028-08-19Us
US7919598 No2009-12-162029-12-16Us
US8221786 No2008-03-212028-03-21Us
US8361972 No2008-03-212028-03-21Us
US8501698 No2007-06-202027-06-20Us
US8685934 No2010-05-262030-05-26Us
US8716251 No2008-03-212028-03-21Us
US9198925 No2000-10-042020-10-04Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.173 mg/mLALOGPS
logP2.52ALOGPS
logP2.11ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)12.57ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area99.38 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity104.93 m3·mol-1ChemAxon
Polarizability42.36 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG: In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165. Epub 2009 Dec 8. [PubMed:19996149 ]
  2. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299 ]
  3. Kasichayanula S, Chang M, Hasegawa M, Liu X, Yamahira N, LaCreta FP, Imai Y, Boulton DW: Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011 Apr;13(4):357-65. doi: 10.1111/j.1463-1326.2011.01359.x. [PubMed:21226818 ]
External Links
ATC CodesA10BD15A10BX09A10BD21
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (868 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Dapagliflozin.
AbirateroneThe serum concentration of Dapagliflozin can be increased when it is combined with Abiraterone.
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Dapagliflozin.
AcetaminophenThe serum concentration of Dapagliflozin can be increased when it is combined with Acetaminophen.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Dapagliflozin.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Dapagliflozin.
AfatinibThe serum concentration of Dapagliflozin can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Albendazole.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Dapagliflozin.
AldosteroneThe serum concentration of Dapagliflozin can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Dapagliflozin can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Dapagliflozin can be increased when it is combined with Alfentanil.
AliskirenThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Aliskiren.
AmantadineThe serum concentration of Dapagliflozin can be increased when it is combined with Amantadine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Dapagliflozin.
Aminohippuric acidThe serum concentration of Dapagliflozin can be increased when it is combined with Aminohippuric acid.
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Dapagliflozin.
AmiodaroneThe serum concentration of Dapagliflozin can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Dapagliflozin can be increased when it is combined with Amitriptyline.
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Dapagliflozin.
AmobarbitalAmobarbital may increase the hypotensive activities of Dapagliflozin.
AmoxapineAmoxapine may increase the hypoglycemic activities of Dapagliflozin.
AmprenavirThe serum concentration of Dapagliflozin can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Dapagliflozin can be increased when it is combined with Amsacrine.
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Dapagliflozin.
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Dapagliflozin.
AprepitantThe serum concentration of Dapagliflozin can be increased when it is combined with Aprepitant.
AripiprazoleAripiprazole may increase the hypotensive activities of Dapagliflozin.
ArtemetherThe metabolism of Dapagliflozin can be decreased when combined with Artemether.
AstemizoleThe serum concentration of Dapagliflozin can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Dapagliflozin can be increased when it is combined with Atazanavir.
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Dapagliflozin.
AtomoxetineThe metabolism of Dapagliflozin can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Dapagliflozin can be increased when it is combined with Atorvastatin.
AzelastineThe serum concentration of Dapagliflozin can be increased when it is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Azilsartan medoxomil.
AzithromycinThe serum concentration of Dapagliflozin can be increased when it is combined with Azithromycin.
BarbitalBarbital may increase the hypotensive activities of Dapagliflozin.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Dapagliflozin.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Dapagliflozin.
BenmoxinBenmoxin may increase the hypoglycemic activities of Dapagliflozin.
BenzocaineThe serum concentration of Dapagliflozin can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Dapagliflozin can be increased when it is combined with Bepridil.
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Dapagliflozin.
BexaroteneThe serum concentration of Dapagliflozin can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Dapagliflozin can be increased when it is combined with Biperiden.
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Dapagliflozin.
BoceprevirThe metabolism of Dapagliflozin can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Dapagliflozin can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Dapagliflozin can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Dapagliflozin can be increased when it is combined with Bosutinib.
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Dapagliflozin.
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Dapagliflozin.
BromocriptineThe serum concentration of Dapagliflozin can be increased when it is combined with Bromocriptine.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Dapagliflozin.
BuprenorphineThe serum concentration of Dapagliflozin can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Dapagliflozin can be decreased when combined with Bupropion.
BuspironeThe serum concentration of Dapagliflozin can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Dapagliflozin can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Dapagliflozin can be increased when it is combined with Caffeine.
CanagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Dapagliflozin.
CapecitabineThe metabolism of Dapagliflozin can be decreased when combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Dapagliflozin.
CarbamazepineThe serum concentration of Dapagliflozin can be decreased when it is combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypoglycemic activities of Dapagliflozin.
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Dapagliflozin.
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Dapagliflozin.
CaspofunginThe serum concentration of Dapagliflozin can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Dapagliflozin can be decreased when combined with Celecoxib.
CeritinibThe serum concentration of Dapagliflozin can be increased when it is combined with Ceritinib.
ChloroquineThe serum concentration of Dapagliflozin can be increased when it is combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dapagliflozin.
ChlorpromazineThe serum concentration of Dapagliflozin can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Dapagliflozin can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Dapagliflozin can be increased when it is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Dapagliflozin.
CholecalciferolThe metabolism of Dapagliflozin can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Dapagliflozin can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Dapagliflozin can be decreased when it is combined with Cholic Acid.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Dapagliflozin.
CimetidineThe serum concentration of Dapagliflozin can be decreased when it is combined with Cimetidine.
CinacalcetThe metabolism of Dapagliflozin can be decreased when combined with Cinacalcet.
CiprofloxacinThe serum concentration of Dapagliflozin can be increased when it is combined with Ciprofloxacin.
CitalopramCitalopram may increase the hypoglycemic activities of Dapagliflozin.
ClarithromycinThe serum concentration of Dapagliflozin can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Dapagliflozin can be decreased when combined with Clemastine.
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Dapagliflozin.
ClobazamThe metabolism of Dapagliflozin can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Dapagliflozin can be increased when it is combined with Clofazimine.
ClomipramineClomipramine may increase the hypoglycemic activities of Dapagliflozin.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Dapagliflozin.
ClotrimazoleThe metabolism of Dapagliflozin can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Dapagliflozin can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Dapagliflozin can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Dapagliflozin can be decreased when combined with Cocaine.
ColchicineThe serum concentration of Dapagliflozin can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Dapagliflozin can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Dapagliflozin can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Dapagliflozin can be decreased when combined with Crizotinib.
CyclophosphamideThe serum concentration of Dapagliflozin can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Dapagliflozin can be decreased when combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Dapagliflozin can be decreased when it is combined with Cyproterone acetate.
DabrafenibThe serum concentration of Dapagliflozin can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Dapagliflozin can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dapagliflozin can be increased when it is combined with Dactinomycin.
DapoxetineDapoxetine may increase the hypoglycemic activities of Dapagliflozin.
DarifenacinThe metabolism of Dapagliflozin can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Dapagliflozin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Dapagliflozin can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Dapagliflozin can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Dapagliflozin can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Dapagliflozin can be decreased when combined with Delavirdine.
DesipramineThe serum concentration of Dapagliflozin can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Dapagliflozin can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Dapagliflozin can be decreased when it is combined with Dexamethasone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dapagliflozin.
DextromethorphanThe serum concentration of Dapagliflozin can be increased when it is combined with Dextromethorphan.
DiclofenacThe serum concentration of Dapagliflozin can be increased when it is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Dapagliflozin.
DiflunisalDiflunisal may increase the hypoglycemic activities of Dapagliflozin.
DigoxinThe serum concentration of Dapagliflozin can be decreased when it is combined with Digoxin.
DihydroergotamineThe metabolism of Dapagliflozin can be decreased when combined with Dihydroergotamine.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Dapagliflozin.
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Dapagliflozin.
DinutuximabThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Dinutuximab.
DiphenhydramineThe metabolism of Dapagliflozin can be decreased when combined with Diphenhydramine.
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Dapagliflozin.
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dapagliflozin.
DoxepinThe serum concentration of Dapagliflozin can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Dapagliflozin can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Dapagliflozin can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Dapagliflozin can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Dapagliflozin can be decreased when combined with Dronedarone.
DuloxetineDapagliflozin may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineThe metabolism of Dapagliflozin can be decreased when combined with Duloxetine.
EfavirenzThe serum concentration of Dapagliflozin can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Dapagliflozin can be increased when it is combined with Elbasvir.
EliglustatThe metabolism of Dapagliflozin can be decreased when combined with Eliglustat.
EmpagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Empagliflozin.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Dapagliflozin.
EnzalutamideThe serum concentration of Dapagliflozin can be increased when it is combined with Enzalutamide.
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Dapagliflozin.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Dapagliflozin.
ErgonovineThe serum concentration of Dapagliflozin can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Dapagliflozin can be increased when it is combined with Ergotamine.
ErythromycinThe metabolism of Dapagliflozin can be decreased when combined with Erythromycin.
EscitalopramEscitalopram may increase the hypoglycemic activities of Dapagliflozin.
Eslicarbazepine acetateThe serum concentration of Dapagliflozin can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Dapagliflozin.
EstramustineThe serum concentration of Dapagliflozin can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Dapagliflozin can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Dapagliflozin can be decreased when it is combined with Estrone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dapagliflozin.
EtoperidoneEtoperidone may increase the hypoglycemic activities of Dapagliflozin.
EtoposideThe serum concentration of Dapagliflozin can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Dapagliflozin can be decreased when it is combined with Etravirine.
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Dapagliflozin.
FenfluramineFenfluramine may increase the hypoglycemic activities of Dapagliflozin.
FentanylThe serum concentration of Dapagliflozin can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Dapagliflozin can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Dapagliflozin can be increased when it is combined with Fidaxomicin.
FloxuridineThe metabolism of Dapagliflozin can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Dapagliflozin can be decreased when combined with Fluconazole.
FluorouracilThe metabolism of Dapagliflozin can be decreased when combined with Fluorouracil.
FluoxetineFluoxetine may increase the hypoglycemic activities of Dapagliflozin.
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Dapagliflozin.
FlupentixolThe serum concentration of Dapagliflozin can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Dapagliflozin can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Dapagliflozin can be increased when it is combined with Flurazepam.
FluvastatinThe metabolism of Dapagliflozin can be decreased when combined with Fluvastatin.
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Dapagliflozin.
FosamprenavirThe metabolism of Dapagliflozin can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Dapagliflozin can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Dapagliflozin.
FosphenytoinThe metabolism of Dapagliflozin can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypoglycemic activities of Dapagliflozin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Dapagliflozin.
Fusidic AcidThe serum concentration of Dapagliflozin can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Dapagliflozin can be increased when it is combined with Gefitinib.
GemfibrozilThe metabolism of Dapagliflozin can be decreased when combined with Gemfibrozil.
GenisteinThe serum concentration of Dapagliflozin can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Dapagliflozin can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Dapagliflozin can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Dapagliflozin can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Dapagliflozin can be increased when it is combined with Grepafloxacin.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Dapagliflozin.
HaloperidolThe serum concentration of Dapagliflozin can be increased when it is combined with Haloperidol.
HexobarbitalHexobarbital may increase the hypotensive activities of Dapagliflozin.
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Dapagliflozin.
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Dapagliflozin.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Dapagliflozin.
HydrocortisoneThe serum concentration of Dapagliflozin can be increased when it is combined with Hydrocortisone.
IdelalisibThe serum concentration of Dapagliflozin can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Dapagliflozin can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Dapagliflozin can be increased when it is combined with Imipramine.
IndalpineIndalpine may increase the hypoglycemic activities of Dapagliflozin.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Dapagliflozin.
IndinavirThe serum concentration of Dapagliflozin can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Dapagliflozin can be increased when it is combined with Indomethacin.
IproclozideIproclozide may increase the hypoglycemic activities of Dapagliflozin.
IproniazidIproniazid may increase the hypoglycemic activities of Dapagliflozin.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Dapagliflozin.
IsavuconazoniumThe metabolism of Dapagliflozin can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Dapagliflozin.
IsoniazidThe metabolism of Dapagliflozin can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Dapagliflozin.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Dapagliflozin.
IsoxsuprineThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Isoxsuprine.
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Dapagliflozin.
ItraconazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Dapagliflozin can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Dapagliflozin can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Dapagliflozin can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Ketoconazole.
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Dapagliflozin.
LansoprazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Dapagliflozin can be increased when it is combined with Lapatinib.
LeflunomideThe metabolism of Dapagliflozin can be decreased when combined with Leflunomide.
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Dapagliflozin.
LevodopaDapagliflozin may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Dapagliflozin can be increased when it is combined with Levofloxacin.
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Dapagliflozin.
LevothyroxineThe serum concentration of Dapagliflozin can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Dapagliflozin can be increased when it is combined with Lidocaine.
LiothyronineThe serum concentration of Dapagliflozin can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Dapagliflozin can be decreased when it is combined with Liotrix.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Dapagliflozin.
LomitapideThe serum concentration of Dapagliflozin can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Dapagliflozin can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Dapagliflozin can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Dapagliflozin can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Dapagliflozin can be decreased when combined with Lorcaserin.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Dapagliflozin.
LovastatinThe metabolism of Dapagliflozin can be decreased when combined with Lovastatin.
Lu AA21004Lu AA21004 may increase the hypoglycemic activities of Dapagliflozin.
LuliconazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Dapagliflozin can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Dapagliflozin can be decreased when combined with Lumefantrine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Dapagliflozin.
MaprotilineThe serum concentration of Dapagliflozin can be increased when it is combined with Maprotiline.
MebanazineMebanazine may increase the hypoglycemic activities of Dapagliflozin.
MebendazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Mebendazole.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Dapagliflozin.
MefloquineThe serum concentration of Dapagliflozin can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Dapagliflozin can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Dapagliflozin can be increased when it is combined with Meprobamate.
MesalazineMesalazine may increase the hypoglycemic activities of Dapagliflozin.
MethadoneThe serum concentration of Dapagliflozin can be increased when it is combined with Methadone.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Dapagliflozin.
MethohexitalMethohexital may increase the hypotensive activities of Dapagliflozin.
MethotrimeprazineThe metabolism of Dapagliflozin can be decreased when combined with Methotrimeprazine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dapagliflozin.
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Dapagliflozin.
Methylene blueMethylene blue may increase the hypoglycemic activities of Dapagliflozin.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Dapagliflozin.
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Dapagliflozin.
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Dapagliflozin.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Dapagliflozin.
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Dapagliflozin.
MexiletineThe metabolism of Dapagliflozin can be decreased when combined with Mexiletine.
MibefradilThe serum concentration of Dapagliflozin can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Dapagliflozin can be decreased when it is combined with Midazolam.
MifepristoneThe metabolism of Dapagliflozin can be decreased when combined with Mifepristone.
MilnacipranMilnacipran may increase the hypoglycemic activities of Dapagliflozin.
MinaprineMinaprine may increase the hypoglycemic activities of Dapagliflozin.
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Dapagliflozin.
MirabegronThe metabolism of Dapagliflozin can be decreased when combined with Mirabegron.
MitomycinThe serum concentration of Dapagliflozin can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Dapagliflozin can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Dapagliflozin can be decreased when it is combined with Mitoxantrone.
MoclobemideMoclobemide may increase the hypoglycemic activities of Dapagliflozin.
ModafinilThe serum concentration of Dapagliflozin can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Dapagliflozin.
MorphineThe serum concentration of Dapagliflozin can be increased when it is combined with Morphine.
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Dapagliflozin.
NafcillinThe serum concentration of Dapagliflozin can be decreased when it is combined with Nafcillin.
NaltrexoneThe serum concentration of Dapagliflozin can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Dapagliflozin can be increased when it is combined with Naringenin.
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Dapagliflozin.
NefazodoneThe serum concentration of Dapagliflozin can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Dapagliflozin can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Dapagliflozin can be increased when it is combined with Neostigmine.
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Dapagliflozin.
NetupitantThe serum concentration of Dapagliflozin can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Dapagliflozin can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypoglycemic activities of Dapagliflozin.
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Dapagliflozin.
NicorandilNicorandil may increase the hypotensive activities of Dapagliflozin.
NicotineThe metabolism of Dapagliflozin can be decreased when combined with Nicotine.
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Dapagliflozin.
NilotinibThe metabolism of Dapagliflozin can be decreased when combined with Nilotinib.
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Dapagliflozin.
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Dapagliflozin.
NitrazepamThe serum concentration of Dapagliflozin can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Dapagliflozin can be increased when it is combined with Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dapagliflozin.
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Dapagliflozin.
NorethisteroneThe serum concentration of Dapagliflozin can be decreased when it is combined with Norethisterone.
OctamoxinOctamoxin may increase the hypoglycemic activities of Dapagliflozin.
OlanzapineOlanzapine may increase the hypoglycemic activities of Dapagliflozin.
OlaparibThe metabolism of Dapagliflozin can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Dapagliflozin.
OmeprazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Dapagliflozin can be increased when it is combined with Osimertinib.
OxandroloneOxandrolone may increase the hypoglycemic activities of Dapagliflozin.
OxymetholoneOxymetholone may increase the hypoglycemic activities of Dapagliflozin.
P-NitrophenolThe serum concentration of Dapagliflozin can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Dapagliflozin can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Dapagliflozin can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Dapagliflozin can be increased when it is combined with Palmitic Acid.
PanobinostatThe metabolism of Dapagliflozin can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Dapagliflozin.
PargylinePargyline may increase the hypoglycemic activities of Dapagliflozin.
ParoxetineParoxetine may increase the hypoglycemic activities of Dapagliflozin.
Peginterferon alfa-2bThe serum concentration of Dapagliflozin can be decreased when it is combined with Peginterferon alfa-2b.
PegvisomantPegvisomant may increase the hypoglycemic activities of Dapagliflozin.
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Dapagliflozin.
PentobarbitalPentobarbital may increase the hypotensive activities of Dapagliflozin.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Dapagliflozin.
PhenelzinePhenelzine may increase the hypoglycemic activities of Dapagliflozin.
PheniprazinePheniprazine may increase the hypoglycemic activities of Dapagliflozin.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Dapagliflozin.
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Dapagliflozin.
PhenytoinThe metabolism of Dapagliflozin can be increased when combined with Phenytoin.
PimozideThe serum concentration of Dapagliflozin can be increased when it is combined with Pimozide.
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Dapagliflozin.
PirlindolePirlindole may increase the hypoglycemic activities of Dapagliflozin.
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Dapagliflozin.
Platelet Activating FactorThe serum concentration of Dapagliflozin can be decreased when it is combined with Platelet Activating Factor.
PonatinibThe serum concentration of Dapagliflozin can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Dapagliflozin can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Dapagliflozin can be increased when it is combined with Pravastatin.
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Dapagliflozin.
PrednisoneThe serum concentration of Dapagliflozin can be increased when it is combined with Prednisone.
PrimidonePrimidone may increase the hypotensive activities of Dapagliflozin.
ProbenecidThe serum concentration of Dapagliflozin can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Dapagliflozin can be decreased when it is combined with Progesterone.
PromazineThe metabolism of Dapagliflozin can be decreased when combined with Promazine.
PromethazineThe serum concentration of Dapagliflozin can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Dapagliflozin can be increased when it is combined with Propafenone.
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Dapagliflozin.
ProtriptylineThe serum concentration of Dapagliflozin can be increased when it is combined with Protriptyline.
PyrimethamineThe metabolism of Dapagliflozin can be decreased when combined with Pyrimethamine.
QuercetinThe serum concentration of Dapagliflozin can be increased when it is combined with Quercetin.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Dapagliflozin.
QuinacrineThe serum concentration of Dapagliflozin can be increased when it is combined with Quinacrine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Dapagliflozin.
QuinidineThe serum concentration of Dapagliflozin can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Dapagliflozin can be increased when it is combined with Quinine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Dapagliflozin.
RanitidineThe serum concentration of Dapagliflozin can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Dapagliflozin can be increased when it is combined with Ranolazine.
RasagilineRasagiline may increase the hypoglycemic activities of Dapagliflozin.
ReboxetineThe serum concentration of Dapagliflozin can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Dapagliflozin can be increased when it is combined with Regorafenib.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Dapagliflozin.
RifabutinThe metabolism of Dapagliflozin can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Dapagliflozin can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Dapagliflozin can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Dapagliflozin can be increased when it is combined with Rilpivirine.
RiociguatThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Riociguat.
RisperidoneDapagliflozin may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Dapagliflozin can be decreased when it is combined with Ritonavir.
RolapitantThe serum concentration of Dapagliflozin can be increased when it is combined with Rolapitant.
RopiniroleThe metabolism of Dapagliflozin can be decreased when combined with Ropinirole.
SafrazineSafrazine may increase the hypoglycemic activities of Dapagliflozin.
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Dapagliflozin.
SaquinavirThe serum concentration of Dapagliflozin can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Dapagliflozin can be increased when it is combined with Scopolamine.
SecobarbitalSecobarbital may increase the hypotensive activities of Dapagliflozin.
SelegilineSelegiline may increase the hypoglycemic activities of Dapagliflozin.
SertralineSertraline may increase the hypoglycemic activities of Dapagliflozin.
SildenafilThe metabolism of Dapagliflozin can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Dapagliflozin can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Dapagliflozin can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Dapagliflozin can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Dapagliflozin can be decreased when it is combined with Sirolimus.
SorafenibThe serum concentration of Dapagliflozin can be increased when it is combined with Sorafenib.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Dapagliflozin.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Dapagliflozin.
St. John's WortThe serum concentration of Dapagliflozin can be decreased when it is combined with St. John's Wort.
StanozololStanozolol may increase the hypoglycemic activities of Dapagliflozin.
StaurosporineThe serum concentration of Dapagliflozin can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Dapagliflozin can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Dapagliflozin can be decreased when it is combined with Streptozocin.
SulfadiazineThe metabolism of Dapagliflozin can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Dapagliflozin can be decreased when combined with Sulfamethoxazole.
SulfinpyrazoneThe serum concentration of Dapagliflozin can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Dapagliflozin can be decreased when combined with Sulfisoxazole.
SumatriptanThe serum concentration of Dapagliflozin can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Dapagliflozin can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Dapagliflozin can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Dapagliflozin can be decreased when it is combined with Tacrolimus.
TamoxifenThe serum concentration of Dapagliflozin can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Dapagliflozin can be increased when it is combined with Taurocholic Acid.
TelaprevirThe metabolism of Dapagliflozin can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Dapagliflozin can be decreased when combined with Telithromycin.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Dapagliflozin.
TemsirolimusThe serum concentration of Dapagliflozin can be increased when it is combined with Temsirolimus.
TenofovirThe metabolism of Dapagliflozin can be decreased when combined with Tenofovir.
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Dapagliflozin.
TerbinafineThe metabolism of Dapagliflozin can be decreased when combined with Terbinafine.
TerfenadineThe serum concentration of Dapagliflozin can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Dapagliflozin can be decreased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Dapagliflozin can be decreased when it is combined with Tesmilifene.
TestosteroneTestosterone may increase the hypoglycemic activities of Dapagliflozin.
TheophyllineThe metabolism of Dapagliflozin can be decreased when combined with Theophylline.
ThiamylalThiamylal may increase the hypotensive activities of Dapagliflozin.
ThiopentalThiopental may increase the hypotensive activities of Dapagliflozin.
ThioridazineThe metabolism of Dapagliflozin can be decreased when combined with Thioridazine.
TicagrelorThe serum concentration of Dapagliflozin can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Dapagliflozin can be decreased when combined with Ticlopidine.
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Dapagliflozin.
TipranavirThe metabolism of Dapagliflozin can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Dapagliflozin.
TocilizumabThe serum concentration of Dapagliflozin can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Dapagliflozin can be decreased when combined with Tolbutamide.
ToloxatoneToloxatone may increase the hypoglycemic activities of Dapagliflozin.
TolvaptanThe serum concentration of Dapagliflozin can be increased when it is combined with Tolvaptan.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Dapagliflozin.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Dapagliflozin.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Dapagliflozin.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Dapagliflozin.
TrazodoneTrazodone may increase the hypoglycemic activities of Dapagliflozin.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Dapagliflozin.
TrifluoperazineThe serum concentration of Dapagliflozin can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Dapagliflozin can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Dapagliflozin can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Dapagliflozin can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Dapagliflozin can be increased when it is combined with Troleandomycin.
Valproic AcidThe metabolism of Dapagliflozin can be decreased when combined with Valproic Acid.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Dapagliflozin.
VemurafenibThe serum concentration of Dapagliflozin can be increased when it is combined with Vemurafenib.
VenlafaxineThe metabolism of Dapagliflozin can be decreased when combined with Venlafaxine.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Dapagliflozin.
VilazodoneVilazodone may increase the hypoglycemic activities of Dapagliflozin.
VinblastineThe serum concentration of Dapagliflozin can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Dapagliflozin can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Dapagliflozin can be increased when it is combined with Vinorelbine.
VoriconazoleThe metabolism of Dapagliflozin can be decreased when combined with Voriconazole.
VortioxetineVortioxetine may increase the hypoglycemic activities of Dapagliflozin.
ZafirlukastThe metabolism of Dapagliflozin can be decreased when combined with Zafirlukast.
ZimelidineZimelidine may increase the hypoglycemic activities of Dapagliflozin.
ZiprasidoneThe metabolism of Dapagliflozin can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonistinhibitor, competitive
General Function:
Low-affinity glucose:sodium symporter activity
Specific Function:
Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules.
Gene Name:
SLC5A2
Uniprot ID:
P31639
Molecular Weight:
72895.995 Da
References
  1. Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, Humphreys WG: In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010 Mar;38(3):405-14. doi: 10.1124/dmd.109.029165. Epub 2009 Dec 8. [PubMed:19996149 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as estriol, 4-hydroxyestrone and 2-hydroxyestriol) and xenobiotics (such as 4-methylumbelliferone, 1-naphthol, 4-nitrophenol, 2-aminophenol, 4-hydroxybiphenyl and menthol). It is capable of 6 alpha-hydr...
Gene Name:
UGT2B4
Uniprot ID:
P06133
Molecular Weight:
60512.035 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Kasichayanula S, Liu X, Lacreta F, Griffen SC, Boulton DW: Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014 Jan;53(1):17-27. doi: 10.1007/s40262-013-0104-3. [PubMed:24105299 ]
Comments
comments powered by Disqus
Drug created on March 19, 2008 10:22 / Updated on October 01, 2016 02:24